Hospital

Compared to endocrine therapy alone, the combination of ribociclib and endocrine therapy lowered the risk of cancer recurrence in patients with early breast cancer by 25.2%.

Innovative experiential learning can provide students with skills necessary to launch successful careers, keeping the pharmacy profession trusted by patients.

Infliximab-dyyb (Zymfentra; Celltrion USA) is a subcutaneous treatment for the maintenance treatment of adults with moderately to severely active ulcerative colitis and Crohn disease.

RSV can create a problematic infection among children 12 months of age or younger, older adults, and in patients with immunocompromised conditions.

This marks the first time that experts have defined cardiovascular-kidney-metabolic syndrome, including the overlap of cardiovascular disease with kidney disease, type 2 diabetes, and obesity.

Mike Schuh, PharmD, MBA, FAPhA, FFSHP, a medication management pharmacist at the Mayo Clinic in Florida, discusses his journey into the pharmacy profession and the evolution of pharmacists from product-oriented to clinical professionals.

Erica Marchese, PharmD, MHA, BCPS, BCOP, BCSCP, discussed the revision of pharmacy and the contributing roles within the pharmacy team.

Penbraya (Pfizer Inc) is the first and only approved pentavalent vaccine that confers protection against the most common meningococcal serogroups—A, B, C, W-135, and Y, in individuals 10 through 25 years of age.

Subcutaneous nivolumab had demonstrated noninferiority of Cavgd28, Cminss, and ORR compared to the intravenous form of treatment.

Women with HIV reported higher rates of physical abuse than men with HIV, but women had more social support from family and friends.

In a recent study, approximately 99% of children who received solid organ transplant and live vaccination against rubella had antibodies 1 to 3 months post-vaccination.

Study authors suggest that saliva samples can be a complementary testing method to provide additional information on pneumococcal carriage and serotypes that may be undetected by nasopharyngeal testing.

The statistically significant and clinically meaningful improvement in disease-free survival is “practice-changing” and may represent a “paradigm shift” in treatment, according to experts.

Biktarvy was found both effective and safe for long-term use in HIV, as well as for patients with mental health conditions.

Integrating immunotherapies will continue to improve patient outcomes and quality of life.

Christina Madison, PharmD, FCCP, AAHIVP, sat down with Amy Marie Merrell, to discuss current issues within sexual health.

Study data suggest that both vaccines induce similar functional antibody responses against pneumococcal serotype 3.

Among individuals who received systemic antibiotics within 8 weeks, 6 months, 12 months, and 24 months of receiving fecal microbiota, RBX2660 prevented recurrence.

This finding underlines the need for methods that address multiple genomic alterations and targeted therapies effective in tumors driven by variations in suppressor genes or transcription factors.

The biosimilar landscape is growing, but the FDA should leverage analytical data to efficiently determine the quality of these products and propel them toward approval, according to a session at the Academy of Managed Care Pharmacy’s Nexus 2023 conference.

Approximately 96% physicians feel it is important to assess patients aged 60 years and older for cognitive impairment, but 48% of these patients have no had assessments from their physician.

The FDA is the only authority that can designate a biosimilar as interchangeable with its reference product, which requires that the product has similar clinical results for the same indication.

There are 3 main medication-related issues for mental health care, which includes polypharmacy, nonadherence to prescribed medication, and underutilization of medications.

Areas of focus for specialty medications include biosimilars, cancer treatments, and drugs across disease states such as inflammatory conditions, HIV, and multiple sclerosis.

Twice-daily tenapanor tablets are recommended for patients with chronic kidney disease who are on dialysis, unresponsive or intolerant of any dose of a phosphate binder therapy.

Following the results of a meta-analysis that reviewed biosimilar trial design and endpoints, investigators urge for greater biosimilar uptake initiatives.

The approval marks the first and only once-daily target therapy for generalized myasthenia gravis for self-administration in this patient population.